Max M B, Schafer S C, Culnane M, Smoller B, Dubner R, Gracely R H
Neurobiology and Anesthesiology Branch, National Institute of Dental Research, Bethesda, MD 20892.
Neurology. 1988 Sep;38(9):1427-32. doi: 10.1212/wnl.38.9.1427.
In a double-blind, randomized, crossover study, 58 patients with postherpetic neuralgia received 6-week courses of amitriptyline, 12.5 to 150 mg/d; lorazepam, 0.5 to 6 mg/d; or lactose placebo. Doses were titrated to the maximum level tolerated. Patients rated pain in a diary, using lists of verbal descriptors. Forty-seven percent of patients reported moderate or greater relief with amitriptyline, 16% with placebo, and 15% with lorazepam. Mean amitriptyline dose was 65 mg/d. Greater relief was associated with higher amitriptyline doses, up to the maximum dose of 150 mg/d, and with higher serum tricyclic levels. Lorazepam did not relieve pain and was associated with severe depressive reactions in four patients.
在一项双盲、随机、交叉研究中,58例带状疱疹后神经痛患者接受了为期6周的治疗,分别服用阿米替林(剂量为12.5至150毫克/天)、劳拉西泮(剂量为0.5至6毫克/天)或乳糖安慰剂。剂量滴定至最大耐受水平。患者通过使用一系列文字描述在日记中对疼痛进行评分。47%的患者报告服用阿米替林后疼痛有中度或更大程度缓解,服用安慰剂的为16%,服用劳拉西泮的为15%。阿米替林的平均剂量为65毫克/天。更高的缓解程度与更高剂量的阿米替林(最高达150毫克/天的最大剂量)以及更高的血清三环类药物水平相关。劳拉西泮未能缓解疼痛,且有4例患者出现严重抑郁反应。